Skip to main content
Fig. 4 | BMC Urology

Fig. 4

From: RUNX3 pathway signature predicts clinical benefits of immune checkpoint inhibition plus tyrosine kinase inhibition in advanced renal cell carcinoma

Fig. 4

RUNX3 pathway signature together with GZMB to predict IO/TKI benefit. (A) Survival benefit of IO/TKI versus TKI monotherapy for PFS in subgroups defined by functional molecules of CD8 + T cells. HR and P values, Cox regression model. (B-E) PFS of IO/TKI or TKI monotherapy in subgroups of (B) high-RUNX3 signature/high-GZMB, (C) high-RUNX3 signature/low-GZMB, (B) low-RUNX3 signature/high-GZMB, (B) low-RUNX3 signature/low-GZMB. P values, Kaplan-Meier analysis, and log-rank test

Back to article page

BMC Urology

ISSN: 1471-2490

Contact us